Condition

Cutaneous Melanoma clinical trials and research

• 27Clinical trials
• 5NIH research projects
• 12Countries

Newest Cutaneous Melanoma clinical trials

All recruiting trials (27)

• Early anti-PD1 therapy before surgery in high-risk stage II melanoma

  This study looks at real-world patients with high-risk stage II melanoma to see if starting anti-PD1 therapy before surgery changes outcomes compared with the usual timing.

  Recruiting AC Camargo Cancer Center · São Paulo, São Paulo · NCT07680699

• Guiding melanoma surgery in children using pathology and genetics

  This pediatric phase 2 trial tests whether using tumor pathology and genetic information to classify risk can guide safer, more appropriate surgery for localized skin melanocytic tumors.

  Recruiting at 13 sites Phase 2 Children's Oncology Group · Oakland, California and 12 other locations · NCT07621614

• First-in-human test of KUP-101A in selected advanced skin cancers

  This early study tests KUP-101A to see if it's safe and tolerable and to gather initial clues about its activity in patients with advanced skin cancers.

  Recruiting at 3 sites Phase 1 Kupando GmbH · Munich, Bavaria and 2 other locations · NCT07600476

• Phase 1 of PF-08046033 for advanced non-small-cell lung cancer, esophageal squamous cell cancer, and cutaneous melanoma

  This Phase 1 study will try the experimental antibody-drug conjugate PF-08046033 in adults whose non-small-cell lung cancer, esophageal squamous cell cancer, or cutaneous melanoma has progressed after standard treatments.

  Recruiting at 20 sites Phase 1 Pfizer · Denver, Colorado and 20 other locations · NCT07519655

• Work-related sun exposure and skin melanoma in the Modena area

  This project will see if people who work outdoors in the Modena area are more likely to develop types of melanoma linked to long-term sun exposure.

  Recruiting University of Modena and Reggio Emilia · Modena, Mo · NCT07251335

• Symptoms from immune checkpoint inhibitor therapy for cutaneous melanoma

  We will follow adults with stage IIB–IV cutaneous melanoma who are receiving immune checkpoint inhibitors to see how their symptoms change over time and which factors are linked to worse symptom patterns.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07148245

• Older adults with early-stage melanoma: WLE alone vs. WLE with SLN biopsy

  This trial tests whether doing wide local excision alone works as well as the standard approach of WLE plus sentinel lymph node biopsy for older adults with early-stage melanoma.

  Recruiting at 176 sites Phase 3 Eastern Cooperative Oncology Group · Birmingham, Alabama and 180 other locations · NCT07068074

• Neoadjuvant ipilimumab, relatlimab, and nivolumab combinations for resectable cutaneous and mucosal melanoma

  This phase 2 trial will test several immunotherapy combinations given before surgery to try to reduce recurrence in adults with resectable stage 3 cutaneous melanoma or resectable mucosal melanoma, including patients predicted or known to respond poorly to standard anti‑PD‑1 therapy.

  Recruiting Phase 2 Melanoma Institute Australia · Wollstonecraft, New South Wales · NCT06999980

• Detecting double-positive (tumor marker/CD45+) cells in the blood of people with metastatic cancer

  This one-day study will test two blood-based methods to find double-positive tumor/CD45+ circulating cells in adults who are about to start treatment for various metastatic cancers.

  Recruiting Institut Claudius Regaud · Toulouse · NCT06967961

• ACTengine IMA203 plus mRNA-4203 for cutaneous melanoma and synovial sarcoma

  This trial tests whether giving the ACTengine IMA203 T‑cell therapy together with the mRNA‑4203 vaccine is safe and helps people with HLA‑A*02:01 unresectable or metastatic cutaneous melanoma or synovial sarcoma who have had prior treatment.

  Recruiting at 4 sites Phase 1 Immatics US, Inc. · San Francisco, California and 3 other locations · NCT06946225

• LNS8801 alone or with pembrolizumab for people whose melanoma has stopped responding.

  This trial will test whether LNS8801, by itself or combined with pembrolizumab, can keep melanoma that progressed after anti‑PD‑1 therapy from growing.

  Recruiting at 9 sites Phase 2/3 Linnaeus Therapeutics, Inc. · Newport Beach, California and 8 other locations · NCT06624644

• Detecting and clearing residual disease in high-risk melanoma patients

  This study is testing if a new combination treatment for high-risk melanoma can help patients with leftover cancer cells in their blood feel better compared to the usual treatment.

  Recruiting Phase 2 University Health Network, Toronto · Toronto, Ontario · NCT06319196

• Using 177Lu-anti-PD-L1 for treating metastatic solid tumors

  This study is testing a new treatment called 177Lu-RAD204 to see if it can safely help people with advanced solid tumors like lung cancer and melanoma.

  Recruiting at 4 sites Early Phase 1 Radiopharm Theranostics, Ltd · Gosford, New South Wales and 5 other locations · NCT06305962

• Using EMLA cream to reduce pain during lymphoscintigraphy for skin cancer

  This study is testing if EMLA cream can help reduce pain for patients getting injections during a lymphoscintigraphy procedure for skin cancer.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT06223659

• Treatment for brain metastases from melanoma using defactinib and avutometinib

  This study is testing if a combination of two drugs, defactinib and avutometinib, can help people with brain tumors from melanoma feel better after their previous treatments didn't work.

  Recruiting at 2 sites Phase 1/2 University of Utah · Iowa City, Iowa and 1 other locations · NCT06194929

• Monoclonal antibody treatment for advanced solid tumors

  This study is testing a new antibody treatment for people with advanced solid tumors to see if it is safe and effective on its own or when combined with another cancer drug.

  Recruiting at 4 sites Phase 1/2 OncoResponse, Inc. · Austin, Texas and 3 other locations · NCT06090266

• Assessing KB707 for treating advanced melanoma and solid tumors

  This study is testing a new treatment called KB707, which is a modified virus, to see if it can help adults with advanced melanoma and other solid tumors who haven't had success with regular treatments.

  Recruiting at 15 sites Phase 1/2 Krystal Biotech, Inc. · Los Angeles, California and 14 other locations · NCT05970497

• Evaluating GI-102 for advanced solid tumors with or without other cancer drugs

  This study is testing a new cancer treatment called GI-102, both on its own and with other cancer drugs, to see how safe it is and how well it works for people with advanced solid tumors.

  Recruiting at 11 sites Phase 1/2 GI Innovation, Inc. · Scottsdale, Arizona and 10 other locations · NCT05824975

• GV20-0251 treatment for advanced solid tumors

  This study is testing a new treatment called GV20-0251 for people with advanced solid tumors that haven't improved with standard treatments, to see how safe it is and if it works better when combined with another medication.

  Recruiting at 10 sites Phase 1/2 GV20 Therapeutics · Los Angeles, California and 12 other locations · NCT05669430

• Monoclonal antibody treatment for advanced cancer

  This study is testing a new antibody treatment for people with advanced cancer to see if it is safe and effective, either on its own or with another medication.

  Recruiting at 17 sites Phase 1/2 Aulos Bioscience, Inc. · Miami, Florida and 16 other locations · NCT05267626

• A new method for monitoring melanoma patients

  This study tests a new way to support and educate patients with low to intermediate risk melanoma to see if it helps them feel less anxious about cancer coming back and encourages them to check their skin regularly.

  Recruiting Herlev and Gentofte Hospital · Copenhagen · NCT05253872

• Observing cancer recurrence using a blood test

  This study is testing a new blood test to see if it can help find out if cancer comes back in people who have been treated for early-stage solid tumors.

  Recruiting at 49 sites Guardant Health, Inc. · Birmingham, Alabama and 56 other locations · NCT05059444

• Evaluating MBS8(1V270) for advanced solid tumors

  This study is testing a new treatment called MBS8(1V270) to see if it is safe and effective for people with advanced solid tumors.

  Recruiting at 5 sites Phase 1 MonTa Biosciences ApS · Herlev and 4 other locations · NCT04855435

• Understanding BAP1 Hereditary Cancer Risks

  This study is trying to find out how common certain cancers are in people with BAP1 gene mutations to help improve screening and treatment for them and their families.

  Recruiting Ohio State University · Columbus, Ohio · NCT04792463

• Investigating lifestyle and psychosocial factors in melanoma patients

  This study looks at how things like mental health, social support, diet, and exercise affect the quality of life and treatment results for people with melanoma.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT04778449

• Evaluating IDE196 for patients with specific solid tumors

  This study is testing a new treatment called IDE196 for people with specific solid tumors that have certain genetic changes to see if it can help shrink their tumors and how safe it is.

  Recruiting at 7 sites Phase 1/2 IDEAYA Biosciences · Los Angeles, California and 14 other locations · NCT03947385

• Pre-operative immunotherapy for stage III melanoma

  This study is testing a combination of two immunotherapy treatments to see if they can shrink tumors in patients with stage III melanoma before they have surgery.

  Recruiting Phase 2 University of Louisville · Louisville, Kentucky · NCT03842943

NIH-funded research (5)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Characterizing the psychological symptoms in melanoma patients on immunotherapy

  A long-term study follows adults with advanced skin cancer who are starting immune checkpoint therapy to understand the pattern of emotional and psychological symptoms they experience.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11402003

• Easing psychological symptoms in women with breast cancer through moderate aerobic exercise

  This project finds out if a regular program of moderate aerobic exercise can reduce anxiety and related psychological symptoms in women undergoing breast cancer treatment while exploring personal, neighborhood, and blood-based (epigenetic) factors that might explain who benefits most.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11328765

• LNS8801: a new cancer drug to help advanced melanoma patients who can’t tolerate immunotherapy

  A small-molecule drug called LNS8801 is being studied to help people with advanced melanoma who can’t tolerate immunotherapy, by working with standard treatments and aiming for fewer side effects.

  NIH research Linnaeus Therapeutics INC · Haddonfield, United States · NIH-11258534

• Understanding how melanoma cells die and resist treatment

  This study is looking into why some people with skin cancer respond better to treatments than others, and how to make those treatments work better with fewer side effects, so that patients can have a better experience and outcome.

  NIH research Thomas Jefferson University · Philadelphia, United States · NIH-11099865

• New treatment for melanoma patients who can't use immunotherapy

  This study is testing a new pill called LNS8801 for people with skin cancer who can’t handle current immunotherapy treatments because of bad side effects, aiming to make cancer treatment easier and more effective for those who need better options.

  NIH research Linnaeus Therapeutics INC · Haddonfield, United States · NIH-11062612

Related topics

Quick answers

How many Cutaneous Melanoma clinical trials are recruiting right now?

27, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 12 countries. The most sites are in United States (18 trials), Australia (4 trials), France (3 trials), Spain (3 trials), Germany (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 7, Phase 2: 5, Phase 1: 4, Phase 2/3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →